Mustang Bio, Inc. Net Debt

Net Debt of MBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt growth rates and interactive chart. Net debt is the sum of all interest-bearing debt (short-term and long-term) minus cash and short-term investments. A positive number indicates the company's total debt exceeds its cash and short-term investments balances, while a negative number means the company has more cash than its total debt. This figure is also used in Enterprise value calculation.


Highlights and Quick Summary

  • Net Debt for the quarter ending September 29, 2021 was $-121 Million (a -5.38% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt increased by 26.47%
  • Annual Net Debt for 2020 was $-95.6 Million (a 108.3% increase from previous year)
  • Annual Net Debt for 2019 was $-45.9 Million (a 34.66% increase from previous year)
  • Annual Net Debt for 2018 was $-34.1 Million (a -44.12% decrease from previous year)
Visit stockrow.com/MBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt of Mustang Bio, Inc.

Most recent Net Debtof MBIO including historical data for past 10 years.

Interactive Chart of Net Debt of Mustang Bio, Inc.

Mustang Bio, Inc. Net Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-120.88 $-127.76 $-127.21
2020 $-95.58 $-72.96 $-69.05 $-42.13 $-95.58
2019 $-47.98 $-59.37 $-69.53 $-27.82 $-45.88
2018 $-34.07 $-40.83 $-46.74 $-54.76 $-34.07
2017 $-60.98 $-67.3 $-73.83 $-75.01 $-60.98
2016 $-27.5 $-8.19 $-27.18

Business Profile of Mustang Bio, Inc.

Sector: Healthcare
Industry: Biotechnology
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.